Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Celyad   /   CELYAD JUNI 2016

Aandeel Celyad BRU:CYAD.BL, BE0974260896

Laatste koers (eur) Verschil Volume
0,651   +0,001   (+0,15%) Dagrange 0,651 - 0,680 13.925   Gem. (3M) 70,4K

CELYAD JUNI 2016

Volgen
326 Posts
Pagina: «« 1 ... 10 11 12 13 14 ... 17 »» | Laatste | Omlaag ↓
  3. [verwijderd] 28 juni 2016 10:42

    Notering Celyad geschorst


    Deel deze pagina:
    ?
    ?
    ?


    Beleggers die hopen op een notering van Celyad zullen even op hun honger moeten blijven zitten. Euronext meldt namelijk zonet dat de notering tijdelijk opgeschort zal blijven omwille van een nakend persbeiricht. Het is koffiedik kijken, maar we herinneren ons wel dat er vorige week nieuws op het aandeel was en dat analist Jan De Kerpel toen al liet weten dat "Het deze week uitkijken is naar de belangrijke fase 3 resultaten van C-Cure".
  10. [verwijderd] 28 juni 2016 11:36
    quote:

    Sky-jumper schreef op 28 juni 2016 11:27:

    In dit opzicht lijkt de grote koersval van gisteren verdacht....
    Ik zie geen verdachtenis. Op basis van speculaties (namelijk de 29 juni werd gespeculeerd als testbericht communicatie) steeg de koers. Daarna kwam hij op een beursconform niveau (ca -3%) en de laatste minuten leek de koers weer iets terug te veren tot de beurs sloot.
  13. [verwijderd] 28 juni 2016 11:57
    lijkt mij toch zeer verdacht. Gisteren van +10% naar -3% op slechts een uur.
    De partijen met groot geld lieten gisteren de prijs nog wat oppompen om hoog te kunnen verkopen. Deze morgen dan een zogenoemd 'test' bericht plaatsen om de schijn van voorkennis te mijden...
    Ik hoop dat ik ongelijk heb want heb toch een aardig aantal celyad-aandelen
  14. [verwijderd] 28 juni 2016 11:59
    quote:

    yvinho schreef op 28 juni 2016 11:57:

    lijkt mij toch zeer verdacht. Gisteren van +10% naar -3% op slechts een uur.
    De partijen met groot geld lieten gisteren de prijs nog wat oppompen om hoog te kunnen verkopen. Deze morgen dan een zogenoemd 'test' bericht plaatsen om de schijn van voorkennis te mijden...
    Ik hoop dat ik ongelijk heb want heb toch een aardig aantal celyad-aandelen
    Een slecht bericht hadden ze vanmorgen gewoon kunnen publiceren
  15. lorcu 28 juni 2016 12:09
    Celyad Announces Results for the
    CHART-1 Phase III Clinical Trial Evaluating C-Cure® Cell Therapy
    A statistically-significant difference on the primary endpoint was not reached; however, a positive trend was seen across all treatment groups, and the primary endpoint was met (p=0.015) for a subset representing 60% of the population of the CHART-1 study (baseline End Diastolic Volume (EDV) segmentation).
    Based on the positive subgroup analysis, Celyad will contact the European Medicines Agency concerning a marketing authorization application.
    Prof. Jozef Bartunek will present the full 39 weeks’ data at the “Hot Line Heart Failure and Innovative Approaches” Late Breaking Clinical Trial Session at ESC on Sunday, August 28, 2016.
    Celyad will seek a partner to accelerate further development and commercialization of C-Cure®.
    Mont-Saint-Guibert, Belgium - Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, with clinical programs in cardiovascular diseases and immuno-oncology, today announced headline results for CHART-1, its European Phase III clinical trial for its lead cardiovascular disease product candidate.
  16. [verwijderd] 28 juni 2016 12:12
    Celyad Announces Results for the CHART-1 Phase III Clinical Trial Evaluating C-Cure® Cell Therapy


    • A statistically-significant difference on the primary endpoint was not reached; however, a positive trend was seen across all treatment groups, and the primary endpoint was met (p=0.015) for a subset representing 60% of the population of the CHART-1 study (baseline End Diastolic Volume (EDV) segmentation).
      Based on the positive subgroup analysis, Celyad will contact the European Medicines Agency concerning a marketing authorization application.
      Prof. Jozef Bartunek will present the full 39 weeks’ data at the “Hot Line Heart Failure and Innovative Approaches” Late Breaking Clinical Trial Session at ESC on Sunday, August 28, 2016.
      Celyad will seek a partner to accelerate further development and commercialization of C-Cure®.
    Mont-Saint-Guibert, Belgium - Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, with clinical programs in cardiovascular diseases and immuno-oncology, today announced headline results for CHART-1, its European Phase III clinical trial for its lead cardiovascular disease product candidate.

    Across the complete trial population, a positive trend was clearly identifiable. However, a statistically-significant difference between treatment and control (sham procedure) was not reached.

    For patients representing 60% of the overall study population and categorized by their End Diastolic Volume (EDV) at inclusion, significance was met for the primary endpoint (p = 0.015). Most importantly, in this subgroup, a strong trend or a statistical significant positive difference was seen in all individual elements of the composite primary endpoint (Mortality, Worsening Heart Failure Events, Quality of Life, 6 minutes Walking Test, End Systolic Volume and Ejection Fraction).

    The study procedure was well tolerated with no safety concerns.

    The CHART-1 trial has been selected by the European Society of Cardiology to be presented at the “Hot Line Heart Failure and Innovative Approaches” Late Breaking Clinical Trial session of the ESC congress in Rome on Sunday, August 28, 2016, at 11:54 am CEST. The European Society of Cardiology has organized a press conference scheduled at 8 am CEST on the same day.

    Based on the positive results seen in this highly clinically relevant group of patients for whom treatment options are currently limited, Celyad will contact the European Medicine Agency concerning a marketing authorization application.

    The Company will use the CHART-1 results as a foundation to optimize the design of the pivotal CHART-2 US trial. In line with this, Celyad confirms it is seeking partnerships to accelerate further development and commercialization of C-Cure®.

    At the Company’s request, trading in Celyad stock (CYAD.BR) will be suspended on June 28, 2016, until the completion of the conference call scheduled at 2:00pm CEST (see details below).
  17. [verwijderd] 28 juni 2016 12:13
    Dr. Christian Homsy, CEO of Celyad, commented: “For the first time in a randomized, double-blind, controlled, Phase III cell therapy study, a positive effect, consistent across all parameters tested, was observed for a substantial, clearly definable, group of heart failure patients.

    CHART-1 has allowed us to better define the patient population that would benefit from
    C-Cure®. We are excited by the prospects for C-Cure® as a new potential treatment option for a highly relevant heart failure population. We are confident that the results will generate interest from potential partners that could accelerate the development and commercialization of
    C-Cure®.”

    Prof. Jozef Bartunek, CHART-1 principal co-investigator, said: “This pioneering study has contributed greatly to our understanding of heart failure disease and the place of regenerative medicine in its management. The results seen for a large clinically relevant number of the patients are ground breaking. We look forward to completing the full analysis and making the data available to the medical community at ESC.

    On behalf of the CHART 1 steering committee we wish to thank the patients and families who were enrolled in the study as well as all the physicians and medical teams that made this study possible.”

    Prof. Gerasimos Filippatos, Immediate Past-President of the Heart Failure Association of the European Society of Cardiology, member of the CHART-1 dissemination committee, said, “The CHART-1 results have identified a well-defined group of patients with symptomatic heart failure despite optimal therapy. Those patients are a large subset of the heart failure population and present specific therapeutic challenges. The outcome of CHART-1 indicate those patients could benefit from this therapy”.

    Conference Call Details

    A conference all will be held on Tuesday, June 28, 2016 at 2:00pm (CEST) / 8:00am (EDT) to review the topline results of the CHART 1 study. Christian Homsy, Chief Executive Officer, will deliver a brief presentation followed by a Q+A session.

    Participants are asked to call the assigned numbers approximately five minutes before the conference call begins.

    The call can be accessed by dialing the numbers below and using the conference ID: 41106485

    International: +44 (0) 1452 560304
    Belgium: 024017052
    France: 0800918149
    UK: 08000738965
    US: 18669265708
326 Posts
Pagina: «« 1 ... 10 11 12 13 14 ... 17 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee